GSK Jan 2025 46.000 call
| Previous close | 0.6500 |
| Open | 0.6500 |
| Bid | 0.3000 |
| Ask | 0.4500 |
| Strike | 46.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 748 |
GlobeNewswireAlector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational human monoclonal antibody, is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN-- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
Simply Wall St.GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with a significant decline in U.S. vaccine sales and ongoing legal issues. In the discussion that follows, we will delve into GSK's financial health, operational inefficiencies, strategic growth initiatives, and external threats to provide a comprehensive overview of the company's current business situation.
Business WireGSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA, September 18, 2024--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
